Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patient Experience Is Key Element For Oncology Dose Optimization

Executive Summary

The push for dose optimization in oncology should incorporate patient experience data, a Friends of Cancer Research White Paper recommends. ‘Tolerability’ is a key element to define in early development, and patient-reported outcomes can help.

You may also be interested in...



Avance Clinical CEO On Biotech Funding Green Shoots, Oncology Study Design Landscape

Avance Clinical’s CEO talks to Scrip about green shoots in US biotech funding, potential partnering in the AI space, the Australia rapid-start draw for early phase trials and the transition in the study design landscape in oncology for first-in-human trials.

A Question Of Intent: How To Avoid US FDA Pitfalls With Academic Oncology Trials

Academic oncology centers and commercial sponsors should work together to ensure that studies begun without ‘registrational intent’ can nevertheless work for US FDA’s needs if circumstances change, a multi-stakeholder white paper urges.

Premarket Dose Optimization Precedent In Oncology Likely Not Available Yet

The current crop of cancer drug approvals were well along in development when Project Optimus launched, meaning they may not have been able to implement the Oncology Center of Excellence’s premarket dose optimization policy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel